Cargando…

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

BACKGROUND: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T cell responses in preclinical studies. METHODS: The first opportu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koup, Richard A., Roederer, Mario, Lamoreaux, Laurie, Fischer, Jennifer, Novik, Laura, Nason, Martha C., Larkin, Brenda D., Enama, Mary E., Ledgerwood, Julie E., Bailer, Robert T., Mascola, John R., Nabel, Gary J., Graham, Barney S.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814848/ https://www.ncbi.nlm.nih.gov/pubmed/20126394 http://dx.doi.org/10.1371/journal.pone.0009015

Ejemplares similares

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
por: Ledgerwood, Julie E., et al.
Publicado: (2015)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
por: Houser, Katherine V., et al.
Publicado: (2018)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa
por: Jaoko, Walter, et al.
Publicado: (2010)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys
por: Letvin, N, et al.
Publicado: (2009)

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors
por: Kreppel, Florian, et al.
Publicado: (2021)

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines
por: Padron-Regalado, Eriko, et al.
Publicado: (2022)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
por: Lv, Jingjing, et al.
Publicado: (2022)

Airway delivery of both a BCG prime and adenoviral boost drives CD4 and CD8 T cells into the lung tissue parenchyma
por: Kaveh, Daryan A., et al.
Publicado: (2020)

Peptide Targeting of Adenoviral Vectors to Augment Tumor Gene Transfer
por: Ballard, Erin N., et al.
Publicado: (2012)

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines
por: Coughlan, Lynda
Publicado: (2020)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs
por: Sullivan, Nancy J, et al.
Publicado: (2006)

Vaccine Development in the Twenty‐First Century: Changing Paradigms for Elusive Viruses
por: Graham, B S, et al.
Publicado: (2009)

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
por: Kim, Eun, et al.
Publicado: (2014)

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022)

Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus
por: Jung, Seo-Yeon, et al.
Publicado: (2018)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Hyperglycosylated resurfaced stabilized GP120 core as an immunogen elicits antibodies targeted at the CD4-binding site
por: Dai, K, et al.
Publicado: (2012)

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
por: Flickinger, John C., et al.
Publicado: (2022)

Targeted adenoviral vectors
por: Vigne, E, et al.
Publicado: (2001)

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
por: Liu, Xinxue, et al.
Publicado: (2021)

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses
por: Precopio, Melissa L., et al.
Publicado: (2007)

Immunogenicity without Efficacy of an Adenoviral Tuberculosis Vaccine in a Stringent Mouse Model for Immunotherapy during Treatment
por: Alyahya, S. Anisah, et al.
Publicado: (2015)

Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
por: Bliss, Carly M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6na9aguo3oj3btbmfh6io5n4ab